Article Sidebar
Views PDF: 222
BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: AN ASSESSMENT OF EFFICACY AND SAFETY IN NHAN DAN GIA DINH HOSPITAL
Main Article Content
Abstract
Introduction: This study was designed to evaluate the eficacy and safety of bevacizumab-containing chemotherapy. Methods: Cross-sectional description was carried on metastatic colorectal cancer patient in Nhan Dan Gia Dinh Hospital from January 2018 to October 2020. Results: The final analysis comprised of 80 patients (male 58.8%; median age 60.6 years and 82.5% had an Eastern Cooperative Oncology Group performance status score ≥1 Chemotherapy included capecitabine plus oxaliplatin (58.7%); 5-fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (11.3%), irinotecan plus 5-FU/LV (8.8%), capecitabine monotherapy (13.7%) and others (7.5%). The median follow – up was 33 months and analysis based on 644 cycles of anticancer therapy including bevacizumab. Median time to treatment failure was 14.6 months (95% confidence interval 12.6 – 16.6). No GI perforations, proteinuria, hypertension crisis, venous thromboembolic events were identified. However, two GI bleeding events occurred (2.5%), no requiring discontinuation of bevacizumab. In addition, grades 3 and 4 febrile neutropenia, diarrhea, peripheral neuropathy and anemia showed cumulative incidences of 8.75%, 2.5%, 2.5% and 2.5%, respectively. Conclusion: Bevacizumab in combination with chemotherapy appears to be well tolerated, and efficacy is consistent with other trial reports. However, patients should be closely monitored to avoid potentially serious events such as neutropenia.
Article Details
Keywords
Bevacizumab, colorectal cancer, metastatic, safety, efficacy
References
2. Van Cutsem E., Cervantes A., Nordlinger B., et al. (2014). Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 25 Suppl 3, iii1-9.
3. Hurwitz H.I., Garcia J., Sandler A.B., et al. (2020). Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev, 86, 102017.
4. Botrel T.E.A., Clark L.G. de O., Paladini L., et al. (2016). Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer, 16(1).
5. Eisenhauer E.A., Therasse P., Bogaerts J., et al. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228–247.
6. Dueck A.C., Mendoza T.R., Mitchell S.A., et al. (2015). Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol, 1(8), 1051–1059.
7. Passardi A., Nanni O., Tassinari D., et al. (2015). Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol, 26(6), 1201–1207.
8. Cunningham D., Lang I., Marcuello E., et al. (2013). Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol, 14(11), 1077–1085.
9. Hammerman et al (2017). The “real-life” impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study.